Real-time Estimate
Cboe BZX
09:51:39 2024-05-28 am EDT
|
5-day change
|
1st Jan Change
|
36.47
USD
|
-1.22%
|
|
-1.47%
|
-6.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
37.27
|
693.2
|
1,803
|
2,099
|
2,169
|
2,433
|
-
|
-
|
Enterprise Value (EV)
1 |
37.27
|
693.2
|
1,395
|
1,794
|
1,745
|
2,433
|
2,433
|
2,433
|
P/E ratio
|
-0.64
x
|
-8.67
x
|
-23.6
x
|
-18.6
x
|
-13.6
x
|
-15.9
x
|
-12.8
x
|
-11.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.4
x
|
93.5
x
|
388
x
|
891
x
|
315
x
|
897
x
|
916
x
|
1,193
x
|
EV / Revenue
|
10.4
x
|
93.5
x
|
388
x
|
891
x
|
315
x
|
897
x
|
916
x
|
1,193
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-14
x
|
-14.3
x
|
-11.1
x
|
-
|
EV / FCF
|
-
|
-
|
-29
x
|
-19.9
x
|
-19.9
x
|
-16.8
x
|
-14.1
x
|
-11.1
x
|
FCF Yield
|
-
|
-
|
-3.45%
|
-5.03%
|
-5.03%
|
-5.96%
|
-7.07%
|
-9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,713
|
39,567
|
46,664
|
47,100
|
54,689
|
65,911
|
-
|
-
|
Reference price
2 |
2.230
|
17.52
|
38.64
|
44.57
|
39.66
|
36.92
|
36.92
|
36.92
|
Announcement Date
|
3/26/20
|
3/29/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.573
|
7.418
|
4.651
|
2.357
|
6.883
|
2.714
|
2.657
|
2.04
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-154.5
|
-170.4
|
-219.8
|
-
|
EBIT
1 |
-55.03
|
-63.35
|
-71.24
|
-115.2
|
-142
|
-176
|
-203.8
|
-230.6
|
Operating Margin
|
-1,540.19%
|
-854.06%
|
-1,531.78%
|
-4,889.01%
|
-2,063.66%
|
-6,484.94%
|
-7,668.4%
|
-11,301.47%
|
Earnings before Tax (EBT)
1 |
-50.88
|
-60.95
|
-70.74
|
-112.3
|
-141.4
|
-155.4
|
-196.8
|
-224
|
Net income
1 |
-50.88
|
-59.78
|
-70.51
|
-112.3
|
-141.4
|
-153.1
|
-195.8
|
-229.8
|
Net margin
|
-1,423.96%
|
-805.88%
|
-1,516.04%
|
-4,765.59%
|
-2,054.76%
|
-5,641.75%
|
-7,368.83%
|
-11,264.71%
|
EPS
2 |
-3.510
|
-2.020
|
-1.640
|
-2.400
|
-2.920
|
-2.315
|
-2.874
|
-3.218
|
Free Cash Flow
1 |
-
|
-
|
-62.16
|
-105.6
|
-109.1
|
-145
|
-172
|
-219
|
FCF margin
|
-
|
-
|
-1,336.44%
|
-4,478.57%
|
-1,585.2%
|
-5,342.1%
|
-6,473.13%
|
-10,735.29%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/29/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.333
|
0.174
|
0.163
|
0.407
|
1.613
|
0.967
|
0.268
|
1.517
|
4.132
|
0.156
|
0.83
|
2.28
|
0.8367
|
0.9733
|
1.3
|
1.3
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-47.63
|
-
|
-41.3
|
-
|
-43.7
|
-44.8
|
-
|
-
|
EBIT
1 |
-20.34
|
-23.79
|
-27.72
|
-27.7
|
-27.88
|
-32.47
|
-33.2
|
-41.24
|
-35.13
|
-40.61
|
-43.02
|
-
|
-45.88
|
-47.8
|
-56.8
|
-56.8
|
Operating Margin
|
-6,108.11%
|
-13,674.14%
|
-17,007.36%
|
-6,804.91%
|
-1,728.77%
|
-3,357.91%
|
-12,389.93%
|
-2,718.46%
|
-850.12%
|
-26,030.77%
|
-5,183.73%
|
-
|
-5,483.05%
|
-4,910.98%
|
-4,369.23%
|
-4,369.23%
|
Earnings before Tax (EBT)
1 |
-20.15
|
-23.05
|
-36
|
-26.78
|
-26.49
|
-29.36
|
-30.5
|
-38.26
|
-43.31
|
-32.81
|
-38.24
|
-
|
-41.28
|
-43.06
|
-56.8
|
-56.8
|
Net income
1 |
-20.15
|
-23.05
|
-36
|
-26.78
|
-26.49
|
-29.36
|
-30.5
|
-38.26
|
-43.31
|
-32.81
|
-37.45
|
-
|
-40.35
|
-42.65
|
-56.8
|
-56.8
|
Net margin
|
-6,050.45%
|
-13,247.13%
|
-22,088.34%
|
-6,580.84%
|
-1,642.1%
|
-3,036.3%
|
-11,381.34%
|
-2,522.08%
|
-1,048.06%
|
-21,030.77%
|
-4,512.05%
|
-
|
-4,822.69%
|
-4,381.86%
|
-4,369.23%
|
-4,369.23%
|
EPS
2 |
-0.4300
|
-0.4900
|
-0.7700
|
-0.5700
|
-0.5600
|
-0.6200
|
-0.6500
|
-0.8100
|
-0.8300
|
-0.5600
|
-0.5775
|
-
|
-0.5925
|
-0.6175
|
-0.8600
|
-0.8600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/5/22
|
8/8/22
|
11/9/22
|
2/28/23
|
5/4/23
|
8/8/23
|
11/2/23
|
2/26/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
408
|
305
|
424
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-62.2
|
-106
|
-109
|
-145
|
-172
|
-219
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
1.25
|
-
|
1.82
|
1
|
1.5
|
2
|
Capex / Sales
|
-
|
-
|
26.85%
|
-
|
26.41%
|
36.84%
|
56.45%
|
98.04%
|
Announcement Date
|
3/26/20
|
3/29/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
36.92
USD Average target price
69
USD Spread / Average Target +86.89% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.91% | 2.43B | | +67.53% | 63.85B | | -0.77% | 41.83B | | +43.51% | 40.47B | | -10.02% | 27.17B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|